Regulus Therapeutics (NASDAQ:RGLS) Upgraded at StockNews.com
StockNews.com upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) to a sell rating in a research note released on Tuesday. Several other research firms have also recently weighed in on RGLS. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, […]
20 Sep 08:20 · The Markets Daily